IWBF DPOING CONTROL ACTIVITY REPORT 2022
The present report summarizes IWBF’s doping control activities in 2022. This report is divided into different sections, namely:

1. Testing & Analytical information
2. Therapeutic Use Exemption (TUE) summary
3. Adverse Analytical Findings (AAF) & Anti-Doping Rule Violation (ADRV)
4. IWBF Registered Testing Pool (RTP) & Additional Testing Pool (ATP) summary

Please do not hesitate to reach out to anti-doping@iwbf.org in case you have any questions related to the information presented in this report.
TESTING & ANALYTICAL INFORMATION

2022

The following tables summarize IWBF’s doping control activities and doping control activities in wheelchair basketball as a general. It provides an overview on how many doping control samples have been collected in 2022 and 2023 and breaks the overall amount of samples down into: In-Competition vs Out-of-Competition and samples collected from male vs female players.
IWBF DOPING CONTROL ACTIVITIES

2022

Total Samples collected in 2022, with IWBF as Testing Authority: 76 Doping Control Samples

Split | In-Competition vs Out-of-Competition

20% In-Competition
80% Out-of-Competition
IWBF DOPING CONTROL ACTIVITIES

2022

Split | Female vs Male Players tested

78% | Male
22% | Female
IWBF DOPING CONTROL ACTIVITIES

2023

Total Samples collected in 2022, with IWBF as Testing Authority: **114 Doping Control Samples**

Split | Female vs Male Players tested

- **57%** Female
- **43%** Male
IWBF DOPING CONTROL ACTIVITIES

2023

Split | In-Competition vs Out-of-Competition

Please note that these figures only include the doping controls where IWBF acted as “Testing Authority” as defined in the World Anti-Doping Code. In addition to these tests, IWBF was active in coordinating various doping controls in cooperation with other Anti-Doping Organizations, such as NADOs and Major Event Organizers.
THERAPEUTIC USE EXEMPTION (TUE)
SUMMARY
2022

IWBF, as the world governing body for wheelchair basketball, is responsible for granting TUEs to international level athletes upon request. Having beard this responsibility, IWBF can provide the following summary as it related to TUEs for the 2022:

• || 08 || TUE applications were received in total by IWBF in 2022.
• || 07 || TUE applications have been approved by IWBF.  
  2 of these approvals were the recognition of national/ NADO TUEs for international purposes.
• || 01 || TUE applications were rejected and/or not concluded
  Please note the reason for rejection, besides others, may include: IWBF not the responsible body for granting a TUE; substance does not require a TUE; insufficient or inconclusive medical evidence, etc.
The following tables summarize IWBF’s results management activities, respectively providing an overview of Adverse Analytical Findings (AAF) resulting from IWBF testing.

<table>
<thead>
<tr>
<th>Case</th>
<th>AAF Substance</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Amphetamine</td>
<td>No ADRV - valid TUE</td>
</tr>
<tr>
<td>2</td>
<td>Tamoxifen</td>
<td>No ADRV - valid TUE</td>
</tr>
</tbody>
</table>

Additional note: in addition to the above mentioned cases, IWBF concluded the results management process for case(s) that were initially handled by other Anti-Doping Organizations.
IWBF did not establish an RTP or Testing Pool in 2022.